Point Biopharma Global Stock Current Ratio
POINT Biopharma Global fundamentals help investors to digest information that contributes to POINT Biopharma's financial success or failures. It also enables traders to predict the movement of POINT Stock. The fundamental analysis module provides a way to measure POINT Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to POINT Biopharma stock.
POINT |
POINT Biopharma Global Company Current Ratio Analysis
POINT Biopharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current POINT Biopharma Current Ratio | 10.90 X |
Most of POINT Biopharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, POINT Biopharma Global is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, POINT Biopharma Global has a Current Ratio of 10.9 times. This is 274.57% higher than that of the Biotechnology sector and 55.71% higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
POINT Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses POINT Biopharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of POINT Biopharma could also be used in its relative valuation, which is a method of valuing POINT Biopharma by comparing valuation metrics of similar companies.POINT Biopharma is currently under evaluation in current ratio category among its peers.
POINT Fundamentals
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.40 % | |||
| Operating Margin | (10.62) % | |||
| Current Valuation | 1 B | |||
| Shares Outstanding | 106.57 M | |||
| Shares Owned By Insiders | 14.97 % | |||
| Shares Owned By Institutions | 48.91 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Book | 3.13 X | |||
| Price To Sales | 5.45 X | |||
| Revenue | 226.58 M | |||
| EBITDA | 127.32 M | |||
| Net Income | 98.29 M | |||
| Cash And Equivalents | 199.43 M | |||
| Cash Per Share | 2.21 X | |||
| Total Debt | 3.56 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 10.90 X | |||
| Book Value Per Share | 4.01 X | |||
| Cash Flow From Operations | 183.52 M | |||
| Short Ratio | 0.98 X | |||
| Earnings Per Share | 1.10 X | |||
| Target Price | 12.5 | |||
| Number Of Employees | 129 | |||
| Beta | -0.003 | |||
| Market Capitalization | 1.33 B | |||
| Total Asset | 578.32 M | |||
| Retained Earnings | 39.01 M | |||
| Working Capital | 451.08 M | |||
| Net Asset | 578.32 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |